October 11, 2026

@michaelokun

Africa's invisible Parkinson's crisis: When a diagnosis and levodopa become luxuries. Parkinson's disease is a growing global health challenge, however in parts of Africa, folks can live for years w/o a diagnosis or access to affordable treatment. Frank Burkybile describes in a compelling 2025 feature in The BMJ how Parkinson's disease in East Africa remains hidden by stigma, limited access to trained health care providers and the high cost of essential medications. Key points: - In Kenya, fewer than 20 neurologists serve more than 50 million folks, leaving enormous gaps in diagnosis and treatment. - Stigma can be devastating, as Parkinson's symptoms may be mistaken for curses or witchcraft, resulting in isolation, abandonment and loss of employment. - Levodopa, one of the most effective and affordable treatments for Parkinson's, remains inconsistently available, forcing some families into financial hardship simply to obtain medication. My take: What resonates most w/ me is that we are not talking about a disease for which we have no treatment. We have levodopa, a medication that has transformed millions of lives, yet access remains profoundly unequal. How can we accept a world where folks must sell their homes to obtain a medication that should be affordable and universally accessible? This is exactly why our Levodopa for All initiative matters. We must stop treating access to Parkinson's medications as a privilege and start treating it as a basic human right. Here are 5 points that resonated w/ me: 1- Parkinson's disease is not just a problem of wealthy countries. It is a global challenge that demands a global response. 2- A diagnosis can change a life, especially in communities where symptoms are misunderstood and stigma can tear families apart. 3- Levodopa should be available to 100% of folks who need it, regardless of where they live or what they can afford. 4- Training nurses, primary care teams and community health workers to recognize and manage Parkinson's could dramatically expand access to care. 5- We need better disease surveillance, stronger local medication supply chains and sustained advocacy.